Trials / Completed
CompletedNCT02614547
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-547 | Administered as intravenous infusion. |
| DRUG | Placebo | Administered as intravenous infusion. |
Timeline
- Start date
- 2015-12-15
- Primary completion
- 2016-06-22
- Completion
- 2016-06-22
- First posted
- 2015-11-25
- Last updated
- 2025-09-15
- Results posted
- 2021-09-13
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02614547. Inclusion in this directory is not an endorsement.